This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
DREAMM-8 is a randomized, parallel-group, open-label phase 3 treatment trial in multiple myeloma. The registry reports 21 enrolled participants assigned to two treatment groups and a primary endpoint of progression-free survival.
| Feature | DREAMM-8 |
|---|---|
| Phase | Phase 3 |
| Condition | Multiple Myeloma |
| Design | Randomized, parallel-group, open-label |
| Allocation | Randomized |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 21 |
| Number of arms | 2 |
| Lead sponsor | GlaxoSmithKline |
| Sponsor type | Industry |
| Status | Active, not recruiting |
| ClinicalTrials.gov | NCT06956170 |
2. Clinical Question
The central statistical question is whether the randomized treatment comparison is associated with a different time to progression or death in participants with multiple myeloma. The primary endpoint is progression-free survival, defined from randomization until the earliest date of disease progression determined by an Independent Review Committee according to International Myeloma Working Group Response Criteria, or death due to any cause.
Population
Participants with multiple myeloma enrolled in the DREAMM-8 phase 3 randomized treatment trial.
Intervention
Belantamab mafodotin plus pomalidomide and dexamethasone.
Comparator
Bortezomib plus pomalidomide and dexamethasone.
Primary question
How does the time to disease progression or death compare between the two randomized treatment groups?
3. Trial Design
Belantamab mafodotin combination
- Belantamab mafodotin
- Pomalidomide
- Dexamethasone
Bortezomib combination
- Bortezomib
- Pomalidomide
- Dexamethasone
The open-label design means treatment assignment was not masked. That matters for endpoints that can involve subjective assessment, although the registry specifically defines the primary PFS endpoint using disease progression determined by an Independent Review Committee according to IMWG Response Criteria.
4. Endpoints
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Progression-Free Survival (PFS) | PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. | Up to approximately 120 weeks |
Definition of disease progression
The registry defines progression as an increase of ≥25% from the lowest value in at least one specified disease measure. Depending on the participant's measurable disease, these include serum M-protein, urine M-protein, the difference between involved and uninvolved serum free light chains, or specified changes in lesions.
| Measure | Registry progression criterion |
|---|---|
| Serum M-protein | Absolute increase ≥0.5 g/dL |
| Serum M-protein when lowest M-protein ≥5 g/dL | Increase ≥1 g/dL |
| Urine M-protein | Absolute increase ≥200 mg/24h |
| Serum free light chains | For participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels with absolute increase >10 mg/dL |
| New lesion | Appearance of a new lesion |
| Measured lesions | ≥50% increase from nadir in the sum of the products of the maximal perpendicular diameters of measured lesions of >1 lesion |
| Previous lesion >1 cm in short axis | ≥50% increase in longest diameter |
This definition illustrates why PFS is more than a simple measurement of tumor size at a single visit. The endpoint combines progression according to prespecified disease criteria with death from any cause, and therefore creates a time-to-event outcome that can incorporate censoring for participants who have not experienced an event by the relevant observation point.
5. Analysis Population
The posted PFS analysis uses the Intent-to-Treat (ITT) Population. The registry defines this population as including all randomized participants whether or not randomized treatment was administered.
The ITT principle preserves the comparison created by randomization. It is especially important when treatment exposure differs from assignment because of discontinuation, treatment changes, or other post-randomization events.
For a time-to-event endpoint, an ITT analysis also means that the analysis population is defined by randomization rather than by whether a participant completed a particular amount of treatment.
6. Statistical Methodology
Kaplan-Meier estimation
Progression-free survival is a time-to-event endpoint. A standard way to describe its distribution is the Kaplan-Meier estimator, which accounts for participants whose event status is not observed during the relevant follow-up period.
Here di is the number of events at time ti and ni is the number at risk immediately before that time.
The registry does not post a Kaplan-Meier curve or a median PFS estimate. Consequently, the reported hazard ratio is the principal posted statistical summary of the primary endpoint.
Cox proportional-hazards model
The registry reports that the PFS hazard ratio was estimated using an unstratified Cox Proportional Hazard model with treatment arm as an explanatory variable.
The hazard ratio is obtained from the treatment coefficient as exp(β). An HR below 1 indicates a lower estimated instantaneous event rate in the belantamab mafodotin combination group relative to the bortezomib combination group, under the fitted model.
Confidence interval
The posted estimate is accompanied by a two-sided 95% confidence interval. Confidence intervals are particularly important in this trial because the enrollment is small relative to many phase 3 randomized studies, and the resulting interval is correspondingly wide.
Statistical hypothesis
The registry lists the hypothesis as Other / not stated. It does not provide a more specific hypothesis statement in the posted statistical analysis.
7. Results: Progression-Free Survival
The ClinicalTrials.gov record posts a statistical analysis for the primary endpoint of progression-free survival. The analysis compares the belantamab mafodotin plus pomalidomide plus dexamethasone group with the bortezomib plus pomalidomide plus dexamethasone group in the ITT population.
Hazard ratio for progression or death
95% CI: 0.10–2.78 · Two-sided 95% CI
Unstratified Cox proportional-hazards model with treatment arm as the explanatory variable.
| Primary endpoint | Belantamab Mafodotin + Pomalidomide + Dexamethasone | Bortezomib + Pomalidomide + Dexamethasone | Effect estimate |
|---|---|---|---|
| Progression-Free Survival | Randomized treatment group | Randomized treatment group | HR 0.53 (95% CI 0.10–2.78) |
An HR of 0.53 means that, under the fitted Cox model, the estimated instantaneous rate of progression or death in the belantamab mafodotin combination group was 0.53 times that in the bortezomib combination group. Equivalently, 0.53 corresponds to a 47% lower estimated hazard because 1 − 0.53 = 0.47.
The HR does not mean that 47% of participants avoided progression, that 47% of participants benefited, or that the treatment reduces every individual's probability of progression or death by exactly 47%.
The 95% confidence interval, 0.10–2.78, is very wide. It contains values below 1 and above 1, indicating substantial statistical uncertainty around the point estimate. The interval describes uncertainty about the estimated treatment effect under the statistical model; it is not a range within which individual patients' treatment effects must fall.
The p-value is not reported in the posted statistical analysis. More generally, a p-value addresses compatibility with a specified null hypothesis; it does not measure the size, clinical importance, or precision of an effect. Here, the confidence interval is especially informative because it shows how much uncertainty surrounds the HR of 0.53.
The Cox interpretation also depends on the model's proportional-hazards framework. A single hazard ratio is most naturally interpreted as a relative hazard over the modeled follow-up when that assumption is reasonably appropriate. The registry does not report a proportional-hazards diagnostic.
Finally, this is an ITT analysis, so the estimate is tied to randomized assignment rather than treatment actually received. The analysis is also unstratified, as specified in the posted Cox model.
8. Reading the PFS Result in Context
The primary estimate and its confidence interval should be considered together rather than separately. The point estimate of 0.53 is below 1, but the 95% CI extends from 0.10 to 2.78. Thus, the point estimate and the uncertainty interval tell different parts of the statistical story.
Point estimate
The HR of 0.53 is the treatment-effect estimate produced by the unstratified Cox model.
Precision
The interval from 0.10 to 2.78 is broad, indicating substantial uncertainty around the point estimate.
Time-to-event meaning
The endpoint incorporates both disease progression and death, rather than measuring only tumor response at a fixed time.
Analysis population
The posted analysis uses all randomized participants in the ITT population, whether or not randomized treatment was administered.
Because the registry does not post a median PFS, event count, Kaplan-Meier estimate, or p-value, the HR and its confidence interval are the principal numerical efficacy results available in the posted statistical analysis.
9. Safety Results
The registry reports serious adverse events by randomized treatment arm as the number affected divided by the number at risk.
| Safety measure | Belantamab Mafodotin + Pomalidomide + Dexamethasone | Bortezomib + Pomalidomide + Dexamethasone |
|---|---|---|
| Serious adverse events | 5/10 | 4/11 |
These counts describe participants affected by serious adverse events among those at risk in each arm. They should not be treated as an efficacy comparison, and they do not by themselves establish a causal difference in safety between treatments.
10. Statistical Methods Explained
Why was a Cox model used for PFS?
PFS records the time until one of two defining events: disease progression or death. A Cox model is designed for this type of time-to-event outcome and provides a hazard ratio that compares the estimated event rates between treatment groups while accommodating right-censored observations.
What does an HR of 0.53 mean?
An HR of 0.53 means that the fitted model estimates the instantaneous rate of progression or death in the belantamab mafodotin combination group to be 0.53 times the rate in the bortezomib combination group. The complementary interpretation is a 47% lower estimated hazard. It is not a 47% absolute reduction in the probability of progression or death.
Why is the confidence interval so important here?
The confidence interval of 0.10–2.78 shows that the statistical uncertainty around the HR is much larger than the point estimate alone suggests. An estimate without its uncertainty can give a misleading impression of precision. Here, the width of the interval is central to interpreting the result.
Why does the ITT population matter?
The ITT population includes all randomized participants whether or not randomized treatment was administered. Analyzing participants according to assignment maintains the treatment comparison created by randomization and avoids defining efficacy around treatment exposure after randomization.
What does “unstratified” mean in the Cox model?
The posted analysis uses an unstratified Cox proportional-hazards model with treatment arm as the explanatory variable. In an unstratified model, the treatment effect is estimated without separate baseline hazard functions for stratification factors. The registry does not list stratification factors for this posted analysis.
Why does PFS include both progression and death?
The registry defines PFS as the time from randomization to the earliest disease progression determined by the Independent Review Committee according to IMWG Response Criteria, or death due to any cause. This composite definition means that death can end a participant's PFS even when a qualifying progression has not otherwise been recorded.
11. Limitations
- Small enrollment: the registry reports 21 enrolled participants. With a small randomized population, treatment-effect estimates can be statistically unstable and confidence intervals can be wide.
- Wide uncertainty: the PFS 95% CI extends from 0.10 to 2.78, demonstrating substantial uncertainty around the HR of 0.53.
- Limited posted efficacy detail: the registry posts the PFS HR and confidence interval but does not report a median PFS, event count, Kaplan-Meier curve, or p-value in the statistical analysis posted on ClinicalTrials.gov for the primary endpoint.
- Open-label design: the study has no masking. Although the primary PFS progression determination is described as being made by an Independent Review Committee, lack of masking remains a design characteristic relevant to interpretation.
- Proportional-hazards assumption: the Cox model produces a single HR, but the registry does not report diagnostics assessing whether the proportional-hazards assumption is appropriate.
- Unstratified analysis: the posted Cox model is unstratified. No adjustment for stratification factors is reported in that analysis.
- Safety interpretation: serious adverse-event counts are small, so descriptive differences should not be treated as a definitive comparative safety analysis.
- Endpoint scope: the posted primary analysis concerns PFS. The registry does not provide additional primary efficacy estimates in the statistical analysis listed here.
12. Why This Trial Matters Statistically
DREAMM-8 is a useful teaching example because it shows how a randomized phase 3 time-to-event analysis should be interpreted when the available numerical evidence consists primarily of a hazard ratio and a confidence interval.
| Concept | How it appears in DREAMM-8 |
|---|---|
| Randomization | The trial is described as randomized with two parallel treatment arms. |
| ITT analysis | The posted PFS analysis uses all randomized participants whether or not randomized treatment was administered. |
| Time-to-event endpoint | PFS measures time from randomization to progression or death. |
| Independent review | Disease progression is determined by an Independent Review Committee according to IMWG Response Criteria. |
| Kaplan-Meier framework | PFS is a time-to-event outcome for which Kaplan-Meier estimation is a standard descriptive approach. |
| Hazard ratio | The primary posted effect measure is the PFS HR. |
| Cox model | The registry reports an unstratified Cox proportional-hazards model with treatment arm as the explanatory variable. |
| Confidence interval | The HR is accompanied by a two-sided 95% CI of 0.10–2.78. |
| Small-sample inference | With 21 enrolled participants, uncertainty around the treatment-effect estimate is an important part of interpretation. |
| Safety analysis | Serious adverse events are reported descriptively as affected participants divided by participants at risk in each arm. |
13. Statistical Concepts in This Trial
Learn more about the methods used in this trial:
14. Related Tutorials
These tutorials provide additional background for interpreting the statistical methods used in DREAMM-8:
15. Related Calculators
16. Sources
- ClinicalTrials.gov: DREAMM-8, NCT06956170.
Continue through the Clinical Biostats knowledge graph
Explore statistical tutorials, calculators, and additional clinical trial analyses covering the methods used to design and interpret randomized clinical studies.
17. Record Summary
DREAMM-8 provides a compact example of randomized time-to-event analysis in a phase 3 clinical trial. The registry reports a primary endpoint of progression-free survival, an ITT analysis population, and an unstratified Cox proportional-hazards model with treatment arm as the explanatory variable. The resulting PFS hazard ratio is 0.53, with a two-sided 95% confidence interval of 0.10–2.78. The point estimate is below 1, while the wide confidence interval demonstrates substantial uncertainty around that estimate. The registry also reports serious adverse events affecting 5/10 participants in the belantamab mafodotin combination group and 4/11 in the bortezomib combination group.